Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II

Anti-Cancer Drugs

Volumn 23, Issue 9, 2012, Pages 906-913

  Szepeshazi, Karoly ^a   Schally, Andrew V ^a   Rick, Ferenc G ^a   Block, Norman L ^a   Vidaurre, Irving ^a   Halmos, Gabor ^a,b   Szalontay, Luca ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

angiogenesis; antineoplastic agents; bombesin analog; gastrin releasing peptide receptors; hepatic cancer; nude mice

Indexed keywords

ANTINEOPLASTIC AGENT; BOMBESIN ANTAGONIST; GASTRIN RELEASING PEPTIDE DERIVATIVE; RC 3940 II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; IN VIVO STUDY; LIVER CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GENE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIN-RELEASING PEPTIDE; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865964166     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328354bd25     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
3. Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): The Alberta HCC algorithm. Can J Gastroenterol 2010; 24:643-650.
4. Duffy A, Greten T. Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010; 4:551-560.
5. Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D. Surgical treatment of hepatocellular carcinoma: Expert consensus statement. HPB (Oxford) 2010; 12:302-310.
6. Reig M, Bruix J. Medical treatments: In association or alone, their roles and their future perspectives: The Western experience. J Hepatobiliary Pancreat Sci 2010; 17:420-421.
7. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement. HPB (Oxford) 2010; 12:313-320.
8. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140:1501-1512, e2.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
10. Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-240.
11. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30:4951-4958.
12. Worns MA, Schuchmann M, Duber C, Otto G, Galle PR, Weinmann A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010; 79:85-92.
13. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Starkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 2010; 9:256.
14. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: The need for randomized phase II trials. J Clin Oncol 2009; 27:833-835.
15. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008; 40:315-322.
16. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007; 18:1457-1466.
17. Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anticancer Drugs 2008; 19:349-358.
18. Li X, Lv Y, Yuan A, Yi S, Ma Y, Li Z. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation. Oncol Rep 2010; 24:441-448.
19. Cai R, Qin Y, Ertl T, Schally A. New pseudononapeptide bombesin antagonists with C-terminal leu-psi(ch2n)tac-nh2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells. Int J Oncol 1995; 6:1165-1172.
20. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, et al. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108:3755-3760.
21. Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, et al. Correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 2010; 31:1839-1846.
22. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrinreleasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995; 55:280-287.
23. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61:317-328.
24. Szepeshazi K, Block NL, Schally AV. The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers. Horm Mol Biol Invest 2010; 1:103-110.
25. Bajo AM, Schally AV, Groot K, Szepeshazi K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004; 90:245-252.
26. Weber HC. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes 2009; 16:66-71.
27. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41:864-880.
28. Goto T, Ishikawa H, Matsumoto K, Nishimura D, Kusaba M, Taura N, et al. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int J Oncol 2008; 33:33-40.
29. Zhang R, Tian L, Chen LJ, Xiao F, Hou JM, Zhao X, et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006; 13: 1263-1271.
30. Amatschek S, Lucas R, Eger A, Pflueger M, Hundsberger H, Knoll C, et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer 2011; 104:469-479.
31. Sato N, Nariuchi H, Tsuruoka N, Nishihara T, Beitz JG, Calabresi P, Frackelton AR Jr. Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 1990; 95:85S-89SS
32. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002; 100:1728-1733.
33. Qin Z, Blankenstein T. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-686.
34. Shukunami C, Oshima Y, Hiraki Y. Chondromodulin-I and tenomodulin: A new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. Biochem Biophys Res Commun 2005; 333:299-307.
35. Bikfalvi A. Platelet factor 4: An inhibitor of angiogenesis. Semin Thromb Hemost 2004; 30:379-385.
36. Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, et al. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res 2005; 25:847-851.
37. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97:425-431.
38. Mino N, Takenaka K, Sonobe M, Miyahara R, Yanagihara K, Otake Y, et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007; 95:250-257.
39. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407-415.
40. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008; 7:85.
41. Tran PL, Vigneron JP, Pericat D, Dubois S, Cazals D, Hervy M, et al. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther 2003; 10:435-444.
42. Utikal J, Gratchev A, Muller-Molinet I, Oerther S, Kzhyshkowska J, Arens N, et al. The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer 2006; 119:2287-2293.
43. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009; 45:1673-1683.
44. Loberg RD, Neeley CK, Adam-Day LL, Fridman Y St, John LN, Nixdorf S, et al. Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Oncol 2005; 26:1699-1705.
45. Ma S, Guan XY, Lee TK, Chan KW. Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 2007; 38:1201-1206.
46. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, et al. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs 2011; 22:245-252.
47. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008; 9:662-673.
48. Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate 2010; 70:1201-1210.
49. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, et al. Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. Br J Cancer 2008; 98: 1999-2005.
50. Nomura T, Huang WC, Zhau HE, Wu D, Xie Z, Mimata H, et al. Beta2- microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive elementbinding protein, and vascular endothelial growth factor axis. Clin Cancer Res 2006; 12:7294-7305.
51. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: A human cell line of endothelial origin. In Vitro Cell Dev Biol 1992; 28A:136-142.
52. Henneke I, Greschus S, Savai R, Korfei M, Markart P, Mahavadi P, et al. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med 2010; 181:611-619.
53. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001; 114:3387-3396.